spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Seattle Genetics 

 HSMN NewsFeed - 3 Nov 2023
Actinium Appoints Lynn Bodarky as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Sep 2021
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 May 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Feb 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2019
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jun 2019
Pfizer to Acquire Array BioPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Mar 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Urology Oncology
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2018
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Regenerative Medicine Personnel
 HSMN NewsFeed - 26 Sep 2017
CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Feb 2016
Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2015
ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 29 Jul 2015
Unum Therapeutics Names Geoffrey Hodge as Senior Vice President, Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Apr 2015
Ultragenyx Appoints Daniel G. Welch to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Mar 2015
Atara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2014
Immune Design Appoints Franklin M. Berger to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Mar 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Feb 2014
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2014
Seattle Genetics Appoints John A. Orwin to Board of Directors
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 2 Dec 2013
Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2013
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Nov 2013
ImmunGene Raises $9 Million in Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Sep 2013
Heat Biologics Appoints Louis C. Bock to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Apr 2013
VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2013
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Oct 2012
Takeda and Millennium Announce European Conditional Marketing Authorization for ADCETRIS(R) (Brentuximab Vedotin)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Mar 2012
Synta Announces Appointment of George Farmer, Ph.D., as Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2012
Seattle Genetics Appoints Dr. Nancy Simonian to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jun 2011
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Nov 2010
Seattle Genetics Announces Additions to Commercial Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Nov 2010
Hyperion Therapeutics Elects David W. Gryska to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Nov 2010
Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Sep 2010
Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 May 2010
Seattle Genetics Names Vice President, Sales and Announces Management Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2009
Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late-Stage Lymphoma Program Brentuximab Vedotin (SGN-35)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Nov 2009
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
Biopharmaceuticals
 HSMN NewsFeed - 13 Oct 2009
Seattle Genetics Names Head of Commercial and Announces Management Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Oct 2009
Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Aug 2009
Alder Biopharmaceuticals Appoints Dr. Mark D. Young Senior VP Pharmaceutical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2009
Emisphere Technologies Appoints Franklin M. Berger to Its Board of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 30 Mar 2009
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Nov 2008
PDL BioPharma Appoints John P. McLaughlin to Become President and CEO Upon Completion of Spin-Off of Biotechnology Assets
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Sep 2008
Seattle Genetics Adds to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2008
Alder Biopharmaceuticals Inc. Completes $40M Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Jul 2007
Agensys Raises $41 Million
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Jun 2007
Seattle Genetics Adds Industry Veterans John P. McLaughlin and Daniel G. Welch to its Board of Directors and Promotes Eric Dobmeier to Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Mar 2007
Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2007
Seattle Genetics Appoints Dr. Tom Reynolds Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2007
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jan 2007
Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Jan 2007
Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Dec 2006
Celgene Names David W. Gryska Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2006
Seattle Genetics Names Pamela Trail, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 17

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 17 additional stories matching:
Seattle Genetics
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.